SEC Form 4 · accession 0001553878-17-000054
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry E Greene
Officer — President
Period of report
Oct 2, 2017
Accepted (ET)
Oct 4, 2017 · 7:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 2, 2017 | M | 85,316 | $21.35 | A | 185,744 | D | |
| Common Stock | Oct 2, 2017 | S | 85,316 | $125.00 | D | 100,428 | D | |
| Common StockF2 | holding | — | — | — | 2,810 | I | By Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $21.35 | Oct 2, 2017 | M | 85,316 | D | — | Dec 8, 2018 | Common Stock | 85,316 | 0 | D |
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017.
- F2The reporting person owns 2,810 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F3The stock option vested as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares each successive three month period thereafter.